Skip to main content
SpringerLink
Log in

Metabolic effects of recombinant human insulin-like growth factor-I in humans: comparison with recombinant human growth hormone

  • Review Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Many of the metabolic actions of growth hormone (GH( are mediated through insulin-like growth factors or somatomedins. Recombinant human insulin-like growth factor-I (rhIGF-I) has a dichotomous insulin-like and GH-like action when used in different clinical situations in humans. Its effets on carbohydrate metabolism show a prominent increase in total insulin sensitivity, causing hypoglycemia in higher doses and maintaining normal glucose homeostasis in lower doses. This polypeptide selectively stimulates whole body protein synthesis with no effect on proteolysis when given in doses of 100 μg/kg subcutaneously twice daily for at least 5–7 days, effects which are indistinguishable from those of GH. This contrasts with the marked suppression of proteolysis observed when higher doses are given, similar to the effects observed with insulin. When used in combination with rhGH, rhIGF-I has a synergistic effect, improving total nitrogen retention in calorically deprived subjects, yet it does not cause any greater enhancement of whole body protein anabolism in normally fed volunteers than giving rhGH and rhIGF-I individually. This suggests a common pathway for IGF-I and GH enhancing protein anabolism in the normally fed state. rhIGF-I also stimulates linear growth in children with defects in the GH receptor. Recent data show that this potent growth factor has a potential advantage over GH in the treatment of severe protein catabolic states, particularly the glucocorticosteroid-dependent model, as it ameliorates the marked increase in protein catabolism caused by the steroids, but without a diabetogenic effect. Here, a brief overview is provided of available human data on the actions of this peptide on carbohydrate, lipid, and protein metabolism, linear growth, and its anabolic effects. rhIGF-I offers promise in the treatment of selective growth disorders and in protein catabolic and insulin-resistant states.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Daughaday WH, Hall K, Raben MS, Salmon WD, VandenBrande JL, Van Wyk JJ (1972) Somatomedin: proposed designation for sulfation factor. Nature 235: 107–108

    PubMed  Google Scholar 

  2. Rinderknecht E, Humbel RE (1978) The amino acid sequence of human IGF-I and its structural homology with proinsulin. J Biol Chem 253: 2769–2776

    PubMed  Google Scholar 

  3. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3–34

    Article  PubMed  Google Scholar 

  4. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ, Roth RA (1988) Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 263: 11486–11492

    PubMed  Google Scholar 

  5. Werner H, Woloschak M, Stannard B, Shen-Orr Z, Roberts CT Jr, LeRoith D (1991) The insulin-like growth factor I receptor: molecular biology, heterogeneity, and regulation. In: LeRoith D (ed) Insulin-like growth factors: molecular and cellular aspects. CRC Press, Boca Raton, Florida, pp 17–47

    Google Scholar 

  6. Guler HP, Zapf J, Froesch ER (1987) Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137–140

    PubMed  Google Scholar 

  7. Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W (1992) Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 75: 1186–1191

    PubMed  Google Scholar 

  8. Clemmons DR, Smith-Banks A, Underwood LE (1992) Reversal of diet-induced catabolism by infusion of recombinant insulin-like factor-I in humans. J Clin Endocrinol Metab 75: 234–238

    PubMed  Google Scholar 

  9. Mauras N, Beaufrere B (1995) rhIGF-I enhances whole body protein anabolism and significantly diminishes the protein-catabolic effects of prednisone in humans, without a diabetogenic effect. J Clin Endocrinol Metab 80: 869–874

    PubMed  Google Scholar 

  10. Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS (1989) Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in awake fasted rat. J Clin Invest 83: 1717–1723

    PubMed  Google Scholar 

  11. Schoenle EJ, Zeonobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER (1991) Recombinant human insulin-like growth factor I (rhIGFI) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 34: 675–679

    PubMed  Google Scholar 

  12. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC (1990) Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N Engl J Med 323: 1425–1426

    PubMed  Google Scholar 

  13. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M, Yoshimasa Y, Kasuga M, Goji K, Nagataki S, Oyasu H, Imura H (1993) Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42: 696–705

    PubMed  Google Scholar 

  14. Usala AL, Madigan T, Burguera B, Sinha MK, Caro JF, Cunningham P, Powell JG, Butler PC (1992) Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. N Engl J Med 327: 853–857

    PubMed  Google Scholar 

  15. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER (1992) Insulin-like growth factor I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 90: 2234–2241

    PubMed  Google Scholar 

  16. Mauras N, Horber FF, Haymond MW (1992) Low dose recombinant human insulin-like growth factor I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metab 75: 1192–1197

    PubMed  Google Scholar 

  17. Hartman ML, Clayton PE, Johnson ML, Celniker A, Perlman AJ, Alberti KGMM, Thorner MO (1993) A low dose euglycemic infusion of rhIGF-I rapidly suppresses fasting-enhanced pulsative GH secretion in humans. J Clin Invest 91: 2453–2462

    PubMed  Google Scholar 

  18. Horber FF, Haymond MW (1990) Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 86: 265–272

    PubMed  Google Scholar 

  19. Schwenk WF, Beaufrere B, Haymond MW (1985) Use of reciprocal pool specific activities to model leucine metabolism in humans. Am J Physiol 249: E646-E650

    PubMed  Google Scholar 

  20. Horber FF, Horber-Feyder CM, Krayer S, Schwenk WF, Haymond MW (1989) Plasma reciprocal pool specific activity predicts that of intracellular free leucine for protein synthesis. Am J Physiol 257: E385-E399

    PubMed  Google Scholar 

  21. Fukagawa NK, Minaker KL, Rowe JW, Goodman MN, Matthews DE, Bier DM, Young VR (1985) Insulin-mediated reduction of whole body protein breakdown. Dose-response effects on leucine metabolism in post-absorptive men. J Clin Invest 76: 2306–2311

    PubMed  Google Scholar 

  22. Clemmons DR (1990) Insulin-like growth factor binding proteins. Trends Endocrinol Metab 2: 411–418

    Google Scholar 

  23. Busby WH, Snyder DK, Clemmons DR (1988) Radioimmunoassay of a 26,000 dalton plasma insulin like growth factor binding protein: control by nutritional variables. J Clin Endocrinol Metab 67: 1225–1230

    PubMed  Google Scholar 

  24. Clemmons DR, Snyder DK, Busby Jr (1991) Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 73: 727–733

    PubMed  Google Scholar 

  25. Zapf J, Schmid C, Guler HP, Waldrogel M, Hauri C, Futo E, Hossenlopp P, Binoux M, Froesch ER (1990) Regulation of binding proteins for insulin-like growth factors (IGF-I) in man: increased expression of IGFBP2 during IGF-I treatment of healthy adults and in patients with extra-pancreatic tumor hypoclycemia. J Clin Invest 86: 952–961

    PubMed  Google Scholar 

  26. Wood WI, Cachianes G, Henzel WJ, Winslow GA, Spencer SA, Hellmiss R, Martin JL, Baxter RC (1988) Cloning and expression of the growth-hormone dependent insulin-like growth factor binding protein. Mol Endocrinol 2: 1176–1185

    PubMed  Google Scholar 

  27. Hintz L, Liu F, Rosenfeld RG, Kemp SF (1981) Plasma somatomedin-binding proteins in hypopituitarism: changes during growth hormone therapy. J Clin Endocrinol Metab 53: 100–104

    PubMed  Google Scholar 

  28. Baxter RC, Martin JL (1986) Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. J Clin Invest 78: 1504–1512

    PubMed  Google Scholar 

  29. Clemmons DR, Thissen JP, Maes M, Keteleggers JM, Underwood LE (1989) Insulin-like growth factor I (IGF-I) infusion into hypophysectomized protein-deprived rats induces specific IGF binding proteins in serum. Endocrinology 125: 2967–2972

    PubMed  Google Scholar 

  30. Clark RG, Mortensen D, Reifsynder D, Mohler M, Etcheverry T, Mukku V (1993) Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3); effects on the glycemic and growth promoting activities of rhIGF-I in the rat. Growth Regul 3: 50–52

    PubMed  Google Scholar 

  31. Blum W, Ranke MB (1990) Use of insulin-like growth factorbinding protein 3 for the evaluation of growth disorders. Horm Res 33 [Suppl 4]: 31–37

    Google Scholar 

  32. Zapf J, Hauri C, Futo E, Hussain M, Rutishauser J, Maack CA, Froesch ER (1995) Intravenously injected insulin-like growth factor (IGF)I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J Clin Invest 95: 179–186

    PubMed  Google Scholar 

  33. Adams S, Moore J, Bagi C, Chu S, Liu C, Rosen D, Sommer A (1995) Protection from hypoglycemic response to IGF-I by administration of IGF-I with its binding protein IGFBP3 in the rat and monkey (abstract). Proceedings of the 77th Annual Meeting of the Endocrine Society. The Endocrine Society Press, Bethesda, Md, P1–295

    Google Scholar 

  34. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH (1994) Growth in growth hormone insensitivity. Trends Endocrinol Metab 5: 296–303

    Google Scholar 

  35. Machwate M, Zerath E, Holy K, Pastoureau P, Marie PJ (1994) IGF-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology 134: 1031–1038

    PubMed  Google Scholar 

  36. Spencer EM, Liu CC, Si EC, Howard GA (1992) In vivo actions of IGF-I on bone formation and resorption in rats. Bone 12: 21–26

    Google Scholar 

  37. Schoenle E, Zapf J, Humbel RE, Froesch ER (1982) Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 296: 252–253

    PubMed  Google Scholar 

  38. Tomas FM, Knowles SE, Chandler CS, Francis GL, Owents PC, Ballard FJ (1993) Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol 137: 413–421

    PubMed  Google Scholar 

  39. Wilton P (1992) Treatment with recombinant human insulin-like growth factor I of children with growth hormone deficiency (Laron syndrome). Kabi Pharmacia study group on insulin-like growth factor I treatment in growth hormone insensitivity syndromes. Acta Paediatr [Suppl] 383: 137–142

    Google Scholar 

  40. Liljdahl SO, Gemzell CA, Plantin LO, Birke G (1961) Effect of human growth hormone in patients with severe burns. Acta Chir Scand 122: 1–14

    PubMed  Google Scholar 

  41. Wilmore DW, Maylan JA, Bristow BF, Mason AD, Pruitt BA (1974) Anabolic effects of growth hormone and high caloric feedings following thermal injury. Surg Gynecol Obstet 128: 875–884

    Google Scholar 

  42. Ziegler TR, Young LS, Manson JM, Wilmore DW (1988) Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition. Ann Surg 208: 6–15

    PubMed  Google Scholar 

  43. Clemmons DR, Williams R, Snyder DK, Underwood LE (1987) Treatment with growth hormone conserves lean body mass during dietary restrictions in obese volunteers. J Clin Endocrinol Metab 64: 878–883

    PubMed  Google Scholar 

  44. Snyder DK, Clemmons DR, Underwood LE (1988) Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects of anabolism, lipolysis and body composition. J Clin Endocrinol Metab 67: 54–61

    PubMed  Google Scholar 

  45. Miell JP, Taylor AM, Jones J, Buchanan CR, Rennie J, Sherwood R, Leicester R, Ross RJ (1992) Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin Endocrinol (Oxf) 37: 542–551

    Google Scholar 

  46. Lieberman SA, Butterfield GE, Harriwon D, Hoffman AR (1994) Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 78: 404–410

    PubMed  Google Scholar 

  47. Clark RG, Mortensen D, Carlsson LMS, Carmignac D, Robinson IC (1993) Effects of GH and IGF-I on body fat in obese dw/dw rats (abstract). Proceedings of the 75th Annual Meeting of the Endocrine Society. The Endocrine Society Press. Bethesda, Md, 1179

    Google Scholar 

  48. Clark RG, Mortensen D, Figari I, Jardieu P (1994) Anabolic and immunologic effects of IGF-I and GH given alone and together to aged rats (abstract). Proceeding of the 76th Annual Meeting of the Endocrine Society. The Endocrine Society Press, Bethesda, Md, 381

    Google Scholar 

  49. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR (1993) Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 91: 391–396

    PubMed  Google Scholar 

  50. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER (1994) Comparison of the effects of GH and IGF-I on substrate oxidation and on insulin sensitivity in GH-deficient humans. J Clin Invest 94: 1126–1133

    PubMed  Google Scholar 

  51. Hazel SJ, Gillespie CM, Moore RJ, Clark RG, Jureidini KF, Martin AA (1994) Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination. Kidney Int 46: 58–68

    PubMed  Google Scholar 

  52. Mauras N (1995) Combined rhGH and rhIGF-I: lack of synergy on whole body protein anabolism in normally fed subjects. J Clin Endocrinol Metab 80: 2633–2637

    PubMed  Google Scholar 

  53. Beaufrere B, Horber FF, Schwenk F, Marsh HM, Matthews D, Gerich JE, Haymond MW (1989) Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Physiol 257: E712-E721

    PubMed  Google Scholar 

  54. Mehls O, Tonshoff B, Kovacs G, Mayer C, Schurek J, Oh J (1993) Interaction between glucocorticoids and growth hormone. Acta Paediatr [Suppl] 388: 77–82

    Google Scholar 

  55. Baron J, Huang Z, Oerter KE, Bacher JD, Cutler GB Jr (1992) Dexamethasone acts locally to inhibit longitudinal bone growth in the rabbit. Am J Physiol 263: E489-E492

    PubMed  Google Scholar 

  56. Heinrichs C, Yanovski JA, Roth AH, Yu M, Domene HM, Yano K, Cutler GB, Baron J (1994) Dexamethasone increases growth hormone receptor mRNA levels in liver and growths plate. J Clin Endocrinol Metab 135: 1113–1118

    Google Scholar 

  57. Horber FF, Marsh HM, Haymond MW (1991) Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes 40: 141–149

    PubMed  Google Scholar 

  58. Zapf J, Schoenle E, Waldrogel M, Sand I, Froesch ER (1981) Effect of trypsin treatment on rat adipocytes on biological effects and binding of insulin and IGFs: further evidence for the action of IGFs through the insulin receptor. Eur J Biochem 113: 605–609

    PubMed  Google Scholar 

  59. Oliverscrona H, Johansson AG, Lindh E, Ljuughall S, Beiglund L, Angelin B (1995) Hormonal regulation of serum lipoprotein levels. Contrasting effects of growth hormone and insulin-like growth factor I. Arterioscler Thromb Vasc Biol 15: 847–849

    PubMed  Google Scholar 

  60. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER (1993) IGF-I stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans. J Clin Invest 92: 2249–2256

    PubMed  Google Scholar 

  61. Hirschberg R, Brunori G, Kopple JD, Guler HP (1993) Effects of insulin-like growth factor I on renal function in normal men. Kidney Int 43: 387–397

    PubMed  Google Scholar 

  62. Miller SB, Moulton M, O'Shea M, Hammerman MR (1994) Effects of IGF-I on renal function in end-stage chronic renal failure. Kidney Int 46: 201–207

    PubMed  Google Scholar 

  63. Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL (1993) Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 124: 73–88

    PubMed  Google Scholar 

  64. Barinaga M (1994) Neurotrophic factors enter the clinic. Science 264: 772–774

    PubMed  Google Scholar 

  65. Rosen CJ, Donahue LR, Hunter SJ (1994) Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 206: 83–102

    PubMed  Google Scholar 

  66. McCarthy TL, Centrella M, Canalis E (1989) IGF-I and bone. Connect Tissue Res 20: 277–282

    PubMed  Google Scholar 

  67. McCarthy TL, Centrella M, Canalis E (1989) Regulatory effects of IGF-I and II on bone collage synthesis in rat calvarial cultures. Endocrinology 124: 301–309

    PubMed  Google Scholar 

  68. Ibbotson KJ, Orcutt CM, D'Souza SM, Paddok CL, Arthur JA, Jankowsky ML, Boyce RW (1992) Contrasting effects of parathyroid hormone and IGF-I in an aged ovariectomized rat model of postmenopausal osteoporosis. J Bone Miner Res 7: 425–432

    PubMed  Google Scholar 

  69. Bagi CM, DeLeon E, Brommage R, Rosen D, Sommer A (1995) Treatment of ovariectomized rats with the complex of rhIGF-I/IGFBP3 increases cortical and calcellous bone mass and improves structure in the femoral neck. Calcif Tissue Int 57: 40–46

    PubMed  Google Scholar 

  70. Bagi C, Meulen M van der, Brommage R, Rosen D, Sommer A (1995) The effect of systemically administered rhIGF-I/IGFBP3 complex on corticol bone strength and structure in ovariectomized rats. Bone 16: 595–565

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nemours Children's Clinic, 807 Nira Street, 32207, Jacksonville, Florida, USA

    Nelly Mauras & Morey W. Haymond

Authors
  1. Nelly Mauras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morey W. Haymond
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mauras, N., Haymond, M.W. Metabolic effects of recombinant human insulin-like growth factor-I in humans: comparison with recombinant human growth hormone. Pediatr Nephrol 10, 318–323 (1996). https://doi.org/10.1007/BF00866769

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00866769

Key words

Search

Navigation